BABonnie Auyeung

Bonnie Auyeung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bonnie Auyeung has a total of 408 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence and patterns of parental disability in UK families: findings from a nationally representative birth cohort study

    by Lijie Zeng, Bonnie Auyeung, Louise Marryat, Jasmin Wertz

  • Open Access

    Prenatal SARS-CoV-2 Exposure and Childhood Illness Requiring Hospitalisation, Growth and Neurodevelopment in Scotland: A National Retrospective Cohort Study

    by Iain Hardie, Louise Marryat, Aja L. Murray, James P. Boardman, Roseanna Jenks, Michael V. Lombardo, Phil Wilson, Bonnie Auyeung

    Background: Evidence regarding the long-term consequences of prenatal SARS-CoV-2 exposure for child health remains limited. In this national cohort study, we examined associations between prenatal SARS-CoV-2 exposure and child growth, illness and neurodevelopmental outcomes up to age 27–30 months in Scotland.Methods: We linked administrative health data from the COVID-19 in Pregnancy in Scotland (COPS) dataset with child health review records, hospital admissions, and other routine health datasets. We included all children conceived after May 18, 2020 and born before April 30, 2022 in Scotland who attended routine 6–8 week and 27–30 month child health reviews. Linear and logistic regression models examined associations between confirmed prenatal SARS-CoV-2 exposure and child growth (weight-for-age, length-for-age, and head circumference-for-age), neurodevelopmental (health visitor developmental concerns), and illness (caregiver concerns regarding child health and hospital admissions for any illness, congenital malformations, respiratory conditions, infections, and perinatal conditions) outcomes. Models adjusted for confounders, covariates and multiple testing. Growth outcomes were assessed at age 6–8 weeks; all other outcomes were assessed up to age 27–30 months.Results: Among 42,696 children included in the study, prenatal SARS-CoV-2 exposure was independently associated with higher odds of hospitalisation for any illness (adjusted odds ratio 1.17, 95% CI 1.11–1.24), respiratory conditions (1.26, 1.17–1.35), and infections (1.20, 1.09–1.32). By contrast, prenatal SARS-CoV-2 exposure was not associated with child growth outcomes, caregiver or health visitor concerns regarding child health or development, or hospitalisation for congenital malformations or perinatal conditions.Interpretation: Prenatal SARS-CoV-2 exposure was associated with higher odds of respiratory and infectious illness requiring hospital admission in early childhood. Continued follow-up of this cohort is warranted to determine whether these findings translate into elevated risks of longer-term respiratory morbidity. Prenatal SARS-CoV-2 exposure was not associated with adverse growth or neurodevelopmental outcomes.

  • Open Access

    Examining the acceptability of providing hair or fingernail samples as a biomarker of physiological stress among older adolescents.

    by Alexandra Alyssa Crocker, Zhuoni Xiao, Bonnie Auyeung, Aja Louise Murray

    Background. Cortisol derived from hair and fingernail samples can be used as a chronic stress biomarker, but feasibility depends on participant acceptability. While concerns regarding hair sampling have been previously documented, perceptions of nail sampling remain underexplored due to the relative novelty of the method.Methods. Participants were recruited via a university participant pool (N = 110, aged 17-22). Participants completed an online survey assessing initial willingness to provide hair and fingernail samples for stress biomarker research, factors discouraging participation, and willingness after watching brief informational videos.Results. Willingness to provide hair and nail samples were highly correlated; 55.5% willing to provide either, 7.3% willing for only hair, and 7.3% willing for only nails. Significant predictors of willingness to provide hair samples were concerns about hair being cut and discomfort with the idea of hair collection, while nail sampling willingness was negatively associated only with discomfort with the idea of nail collection. There was no significant change in willingness to provide either sample following the presentation of an informational video Discussion. Based on acceptability ratings, nail sampling for cortisol appears to be feasible for adolescent health research, yielding acceptability levels strongly correlated with and comparable to hair sampling. Correlates of acceptability mainly concerned discomfort with the idea of hair/nail sampling, though concerns about having their hair cut was an additional correlate of willingness for hair sampling. These correlates provide insights into the concerns that require addressing to enhance willingness to provide hair/nail samples.

  • Open Access

    Divergent Paths of Risk: Exploring the Role of Cognitive Control in Adolescent Positive and Negative Risk Taking

    by Hyeji Lee, Stella Haffner, Bonnie Auyeung, Nicolas Chevalier

    Taking risks is a crucial part of adolescent development. Risk taking encompasses both positive (i.e., socially valued) and negative (e.g., potentially life-threatening) behaviours. Why do some adolescents engage more in negative risk taking while others lean towards positive risk taking? This study tested the hypotheses that greater cognitive control and greater learning under uncertainty may support both engagement in positive risk taking and restraint from negative risk taking. Using online tasks and questionnaires, we assessed various components of cognitive control, risk taking, and learning under uncertainty in 111 adolescents aged 12-18 years (60% female, 60% White). As hypothesised, higher cognitive control (especially effortful control and proactive control) and greater learning under uncertainty were associated with reduced negative risk taking and, to a lesser extent, elevated positive risk taking. Further, these associations diminished with age, perhaps because external factors such as opportunity and social context increasingly influence risk taking in older adolescents. Although causality cannot be ascertained, these findings suggest that cognitive control and learning under uncertainty may support adaptive risk taking in adolescence, potentially reducing harmful risks while promoting beneficial ones.

  • Open Access

    Associations between Reward and Future-related Orientations and General and Specific Mental Health Issues in Adolescence

    by Yi Yang, Xinxin Zhu, Bonnie Auyeung, Ingrid Obsuth, Aja Louise Murray

    Background: Adolescence is characterised by a peak in sensation seeking accompanied by gradually developing self-control skills. Adolescents typically show steeper delay discounting performance than other age groups; a feature that is transdiagnostically related to a variety of mental health disorders. However, delay discounting performance is not a singular mental process but involves the competition between reward seeking and future orientation, which are usually operationalised as probability and time discounting tasks, respectively. Methods: To clarify the specific relations between the reward seeking and future orientation components of delay discounting and different types of mental health problems, two bi-factor models and a series of structural equation models (SEMs) were fitted to multi-informant (parent and adolescent self-report) mental health data from a large longitudinal study. Results: Results suggested support for: 1) a general mental health p-factor and a transdiagnostic relation of time discounting to this factor based on parent reports; 2) time discounting (future orientation/time-waiting) as a protective factor for conduct and ADHD problems, but a risk factor for emotional problems; and 3) risk discounting preference (impulsive sensation seeking/risk-taking) as a protective factor for emotional and peer problems. Conclusions: The findings highlight that time and risk aspects of delay discounting play partly distinct roles in different mental health problems and illuminate which aspects of delay discounting should be targeted for different mental health concerns.

  • Open Access

    A population-based matched cohort study of major congenital anomalies following COVID-19 vaccination and SARS-CoV-2 infection

    by Clara Calvert, Jade Carruthers, Cheryl Denny, Jack Donaghy, Lisa E. M. Hopcroft, Leanne Hopkins, Anna Goulding, Laura Lindsay, Terry McLaughlin, Emily Moore, et al.

    Evidence on associations between COVID-19 vaccination or SARS-CoV-2 infection and the risk of congenital anomalies is limited. Here we report a national, population-based, matched cohort study using linked electronic health records from Scotland (May 2020-April 2022) to estimate the association between COVID-19 vaccination and, separately, SARS-CoV-2 infection between six weeks pre-conception and 19 weeks and six days gestation and the risk of [1] any major congenital anomaly and [2] any non-genetic major congenital anomaly. Mothers vaccinated in this pregnancy exposure period mostly received an mRNA vaccine (73.7% Pfizer-BioNTech BNT162b2 and 7.9% Moderna mRNA-1273). Of the 6731 babies whose mothers were vaccinated in the pregnancy exposure period, 153 had any anomaly and 120 had a non-genetic anomaly. Primary analyses find no association between any vaccination and any anomaly (adjusted Odds Ratio [aOR] = 1.01, 95% Confidence Interval [CI] = 0.83-1.24) or non-genetic anomalies (aOR = 1.00, 95% CI = 0.81-1.22). Primary analyses also find no association between SARS-CoV-2 infection and any anomaly (aOR = 1.02, 95% CI = 0.66-1.60) or non-genetic anomalies (aOR = 0.94, 95% CI = 0.57-1.54). Findings are robust to sensitivity analyses. These data provide reassurance on the safety of vaccination, in particular mRNA vaccines, just before or in early pregnancy.


  • Open Access

    Diagnostic model development for schizophrenia based on peripheral blood mononuclear cell subtype-specific expression of metabolic markers

    by Jihan K. Zaki, Santiago G. Lago, Nitin Rustogi, Shiral S. Gangadin, Jiri Benacek, Geertje F. van Rees, Frieder Haenisch, Jantine A. Broek, Paula Suarez-Pinilla, Tillmann Ruland, et al.

    A significant proportion of the personal and economic burden of schizophrenia can be attributed to the late diagnosis or misdiagnosis of the disorder. A novel, objective diagnostic approaches could facilitate the early detection and treatment of schizophrenia and improve patient outcomes. In the present study, we aimed to identify robust schizophrenia-specific blood biomarkers, with the goal of developing an accurate diagnostic model. The levels of selected serum and peripheral blood mononuclear cell (PBMC) markers relevant to metabolic and immune function were measured in healthy controls (n = 26) and recent-onset schizophrenia patients (n = 36) using multiplexed immunoassays and flow cytometry. Analysis of covariance revealed significant upregulation of insulin receptor (IR) and fatty acid translocase (CD36) levels in T helper cells (F = 10.75, P = 0.002, Q = 0.024 and F = 21.58, P = 2.8 × 10−5, Q = 0.0004, respectively), as well as downregulation of glucose transporter 1 (GLUT1) expression in monocytes (F = 21.46, P = 2.9 × 10−5, Q = 0.0004). The most robust predictors, monocyte GLUT1 and T helper cell CD36, were used to develop a diagnostic model, which showed a leave-one-out cross-validated area under the receiver operating characteristic curve (AUC) of 0.78 (95% CI: 0.66–0.92). The diagnostic model was validated in two independent datasets. The model was able to distinguish first-onset, drug-naïve schizophrenia patients (n = 34) from healthy controls (n = 39) with an AUC of 0.75 (95% CI: 0.64–0.86), and also differentiated schizophrenia patients (n = 22) from patients with other neuropsychiatric conditions, including bipolar disorder, major depressive disorder and autism spectrum disorder (n = 68), with an AUC of 0.83 (95% CI: 0.75–0.92). These findings indicate that PBMC-derived biomarkers have the potential to support an accurate and objective differential diagnosis of schizophrenia.


  • Open Access

    A population-based matched cohort study of early pregnancy outcomes following COVID-19 vaccination and SARS-CoV-2 infection

    by Clara Calvert, Jade Carruthers, Cheryl Denny, Jack Donaghy, Sam Hillman, Lisa E. M. Hopcroft, Leanne Hopkins, Anna Goulding, Laura Lindsay, Terry McLaughlin, et al.

    Data on the safety of COVID-19 vaccines in early pregnancy are limited. We conducted a national, population-based, matched cohort study assessing associations between COVID-19 vaccination and miscarriage prior to 20 weeks gestation and, separately, ectopic pregnancy. We identified women in Scotland vaccinated between 6 weeks preconception and 19 weeks 6 days gestation (for miscarriage; n = 18,780) or 2 weeks 6 days gestation (for ectopic; n = 10,570). Matched, unvaccinated women from the pre-pandemic and, separately, pandemic periods were used as controls. Here we show no association between vaccination and miscarriage (adjusted Odds Ratio [aOR], pre-pandemic controls = 1.02, 95% Confidence Interval [CI] = 0.96–1.09) or ectopic pregnancy (aOR = 1.13, 95% CI = 0.92–1.38). We undertook additional analyses examining confirmed SARS-CoV-2 infection as the exposure and similarly found no association with miscarriage or ectopic pregnancy. Our findings support current recommendations that vaccination remains the safest way for pregnant women to protect themselves and their babies from COVID-19.


  • Open Access

    COVID-19 vaccination and SARS-CoV-2 infection in early pregnancy and the risk of major congenital anomalies: a national population-based cohort study

    by Rachael Wood, Clara Calvert, Jade Carruthers, Cheryl Denny, Jack Donaghy, Lisa Hopcoft, Leanne Hopkins, Anna Goulding, Laura Lindsay, Terry McLaughlin, et al.

    Evidence on associations between COVID-19 vaccination or SARS-CoV-2 infection and the risk of congenital anomalies is limited. We conducted a national, population-based, matched cohort study to estimate the association between COVID-19 vaccination and, separately, SARS-CoV-2 infection between six weeks pre-conception and 19 weeks and six days gestation and the risk of [1] any congenital anomaly and; [2] non-genetic anomalies. Mothers vaccinated in this pregnancy exposure period mostly received an mRNA vaccine (73.7% Pfizer-BioNTech BNT162b2 and 7.9% Moderna mRNA-1273). Of the 6,731 babies whose mothers were vaccinated in the pregnancy exposure period, 153 had any congenital anomaly and 120 had a non-genetic anomaly. Primary analyses found no association between vaccination and any anomaly (adjusted Odds Ratio [aOR] = 1.01, 95% Confidence Interval [CI] = 0.83–1.24) or non-genetic anomalies (aOR = 1.00, 95% CI = 0.81–1.22). Primary analyses also found no association between SARS-CoV-2 infection and any anomaly (aOR = 1.02, 95% CI = 0.66–1.60) or non-genetic anomalies (aOR = 0.94, 95% CI = 0.57–1.54). Findings were robust to sensitivity analyses. These data provide reassurance on the safety of vaccination, in particular mRNA vaccines, just before or in early pregnancy.

  • Empathizing, systemizing, empathizing‐systemizing difference and their association with autistic traits in children with autism spectrum disorder, with and without intellectual disability

    by Ning Pan, Bonnie Auyeung, Xin Wang, Li‐Zi Lin, Hai‐Lin Li, Xiao‐Ling Zhan, Cheng‐Kai Jin, Jin Jing, Xiu‐Hong Li

    Empathizing, systemizing, and empathizing‐systemizing difference can be linked to autistic traits in the general adult population and those with autism spectrum disorder (ASD), but these profiles and associations remain unclear in children with ASD, with and without intellectual disability (ASD + ID; ASD‐noID). We recruited three groups including 160 boys with ASD (73 ASD + ID; 87 ASD‐noID) and 99 typically developing (TD) boys (6–12 years). We measured empathizing, systemizing, and empathizing‐systemizing difference using the parent‐reported child Empathy and Systemizing Quotient (EQ‐C/SQ‐C). We measured autistic traits using the Social Responsiveness Scale (SRS). Among the three groups, children with ASD + ID and ASD‐noID scored lower on the EQ‐C and SQ‐C than TD children (all p < 0.001). There was no difference in the EQ‐C between children with ASD + ID and ASD‐noID (16.59 ± 5.53 vs. 16.23 ± 5.85, p = 0.973), and the difference in the SQ‐C attenuated to null when adjusting for intelligence between children with ASD‐noID and TD children (18.89 ± 7.80 vs. 24.15 ± 6.73, p = 0.089). Children with ASD + ID scored higher on empathizing‐systemizing difference than TD children but lower than children with ASD‐noID (all p < 0.05). Negative associations between EQ‐C and all autistic traits, null associations between SQ‐C and all autistic traits, and positive associations between empathizing‐systemizing difference and all autistic traits were found in all groups. We observed differences in empathizing, systemizing, and empathizing‐systemizing difference and the consistency of their associations with autistic traits among the three groups. Our findings provide implication that behavioral interventions of ASD should consider the balance of empathizing and systemizing.Lay Summary: We examined the profiles of empathizing, systemizing, and empathizing‐systemizing difference in children with autism spectrum disorder, with and without intellectual disability (ASD + ID; ASD‐noID), and typically developing (TD) children aged 6–12 years. We observed differences in these profiles and the consistency of their associations with autistic traits among the three groups. Empathizing and empathizing‐systemizing difference, rather than systemizing, were associated with autistic traits within the three groups. Our findings provide implication that behavioral interventions of ASD should consider these imbalance profiles.